|
Real Time
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 0,6200 EUR | +14,60% |
|
-11,17% | -59,64% |
| 13/07 | AB Science staakt drie klinische studies met masitinib | MT |
| 10/07 | AB Science rationaliseert portefeuille en focust op twee moleculen |  |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Evolutie 1 maand | Evolutie 3 maanden | Var. 1 jan | Varia. 1j. | Varia. 3j. | Varia. 5j. | Varia. 10j. | Kap.($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +14,60% | -11,17% | -19,79% | -38,00% | -59,64% | -54,55% | -82,21% | -94,80% | -95,52% | 49,8 mln. | |
| +0,32% | -0,66% | +0,49% | +16,08% | +23,69% | +64,21% | +23,18% | +70,91% | +123,21% | 322 mld. | |
| +0,49% | +1,52% | -1,20% | +31,54% | +17,37% | +32,99% | -12,31% | -17,58% | +46,42% | 71,6 mld. | |
| -0,91% | +0,74% | +3,89% | +29,05% | +22,64% | +39,85% | +92,63% | +103,55% | +722,93% | 9,79 mld. | |
| -1,53% | -5,47% | -5,56% | +5,10% | -0,46% | -1,91% | -7,52% | -28,33% | +47,97% | 8,39 mld. | |
| +1,80% | -1,99% | -8,78% | -20,92% | -36,60% | -15,78% | -13,19% | -36,29% | - | 4,3 mld. | |
| -0,68% | -1,87% | +4,85% | -19,76% | -34,61% | -34,78% | +6,01% | +37,23% | +80,39% | 3,81 mld. | |
| +3,08% | -1,41% | -14,43% | +10,70% | +23,15% | -12,94% | +15,81% | -35,76% | - | 3,58 mld. | |
| -2,15% | -3,40% | -7,12% | -6,73% | -10,20% | +25,70% | +41,55% | +66,90% | +100,49% | 2,59 mld. | |
| +0,85% | +9,88% | +0,90% | -11,31% | -12,37% | -0,25% | -3,21% | +71,92% | - | 2,25 mld. | |
| -.--% | +4,37% | -0,11% | -7,82% | -12,48% | -22,39% | -14,67% | -5,56% | -39,97% | 1,76 mld. | |
| +1,97% | -6,17% | -6,70% | -15,52% | -9,45% | -29,35% | +19,46% | -32,74% | - | 1,74 mld. | |
| -.--% | -.--% | - | - | - | - | - | - | - | 1,64 mld. | |
| -5,32% | +8,99% | +23,79% | +60,62% | +174,51% | +228,52% | +1.540,28% | +708,71% | - | 1,27 mld. | |
| +15,69% | +9,46% | -2,80% | -32,73% | -34,52% | +59,89% | +50,70% | +29,67% | +488,04% | 1,26 mld. | |
| +1,59% | -2,26% | -17,78% | -34,40% | -22,74% | -53,23% | -30,21% | - | - | 1,1 mld. | |
| -5,63% | -10,35% | -5,86% | -11,58% | -17,10% | -13,27% | +12,88% | +64,96% | +61,57% | 1,06 mld. | |
| +2,91% | -10,88% | -35,24% | -15,43% | -1,94% | -17,79% | +63,13% | -13,70% | - | 982 mln. | |
| +1,77% | +7,11% | +1,77% | -17,94% | -20,94% | -36,23% | -73,87% | -82,72% | - | 913 mln. | |
| 0,00% | -0,41% | -2,42% | -13,26% | -12,95% | -42,79% | -10,70% | -47,84% | -66,01% | 866 mln. | |
| Gemiddelde | +1,44% | -0,53% | -4,85% | -4,86% | -1,29% | +6,10% | +85,14% | +42,14% | +133,59% | 22,03 mld. | |
| Gewogen gemiddelde per kap. | +0,33% | -0,13% | -0,16% | +17,06% | +20,24% | +53,12% | +21,72% | +53,27% | +121,91% |
Kies jouw editie
Alle financiële informatie op nationaal niveau
